Short Term Trading Week Starting: 9 Jan, page-112

STTCOMP TWH, FA LONG
last traded sp : 1.2c
mc: 361.4K
In suspension for RTO of Auscann .
Recent 20:1 consolidation and credit raising at 1c

• Successful $5m capital raise completed with significant interest from institutional and HNW investors
and strong support from domestic and international markets
• 100% acceptances received for acquisition of AusCann
• ASX conditional approval for reinstatement received
• Re-listing on track and expected in mid to late January 2017
• Funds to be used to progress medical cannabis operations including licensing applications to
commence growing operations in Australia
• AusCann to leverage IP of largest shareholder and strategic partner, Canopy Growth Corporation,
Canada’s largest and leading medicinal cannabis company.
Canopy Growth Corporation MC 1.2B CAD

Also
Release Date: 10/11/16 12:28
TW Holdings Limited (ASX:TWH) advises that AusCann Group Holdings Limited (“AusCann”) has entered into a binding agreement to form a joint-venture with Chilean-based medical cannabis group Fundación Daya (“Daya”). Daya is the only group to have held a medical cannabis production licence in Chile and the joint venture provides AusCann with the immediate ability to commence grow operations with a strong local partner already holding necessary licences and permits. AusCann and Daya will form a 50/50 joint-venture company “DayaCann” which will focus on becoming South America’s leading medical cannabis group and a key player in the global supply chain operating from a very stable, progressive and low cost base. A number of groups have already expressed interest in accessing plant material for a range of uses providing a strong base from which to grow future crop size and revenues. All necessary infrastructure is already in place. Planting of the crop will commence immediately with harvesting expected in May 2017. This plant material will be sold to several groups conducting research, clinical trials and developing products where AusCann and Daya have long-standing relationships. These activities will complement AusCann’s proposed activities in Australia and provide shareholders with diversified exposure to the rapidly growing global medical cannabis sector